USA: Biopharmaceuticals Pfizer Expands Global R&D Network

Editor: Alexander Stark

Pfizer broke ground on a state-of-the art Research and Development (R&D) and process development facility in Chesterfield, MO. The new campus will be owned by the biopharmaceutical company and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area.

Related Companies

Pfizer R&D Facility
Pfizer R&D Facility
(Source: Business Wire)

St. Louis/USA — The company expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019. The facility will provide approximately 89,000 square meters of R&D space to house the Bio-Therapeutics Pharmaceutical Sciences group and enabling partners. This team is responsible for advancing biologics, vaccines, and the gene therapy portfolio by developing manufacturing processes and dosage forms applying state-of-the-art analytical technologies, conducting non-GMP manufacturing and scale-up studies. This work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars, the company claims.

“We’ve been proud to call Missouri home since 2002,” said John Ludwig, Senior Vice President of Biotherapeutics Pharmaceutical Sciences for Pfizer. “During this time, we’ve benefitted from the excellent life sciences workforce based in Missouri, and also from a strong partnership with the State, St. Louis County, and the St. Louis Economic Development Partnership. All of these were important factors as we sought a new home where we could continue to evolve our business over the coming years.”

New features of the campus will include a floor plan which provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces and increased conferencing technologies where researchers can collaborate. CRG is providing design-build management services, partnering with Clayco as the design-builder. All architecture, landscape design, engineering, interior and lab/process design was provided by Forum and Ewing Cole.

The St. Louis site is part of Pfizer’s worldwide R&D network, which includes locations in La Jolla, Calif.; Pearl River, NY; Groton, Conn.; and Cambridge and Andover, Mass.